MedPath

FDA Advisers to Consider Emergent’s (EBS) Narcan Spray as OTC Overdose Antidote - Bloomberg

US health advisers to review Emergent BioSolutions' Narcan nasal spray for over-the-counter sale, aiming to increase access amid opioid crisis. FDA advisory panels to assess safety for nonprescription use, with a decision expected by March 29.


Reference News

FDA Advisers to Consider Emergent’s (EBS) Narcan Spray as OTC Overdose Antidote - Bloomberg

US health advisers to review Emergent BioSolutions' Narcan nasal spray for over-the-counter sale, aiming to increase access amid opioid crisis. FDA advisory panels to assess safety for nonprescription use, with a decision expected by March 29.

© Copyright 2025. All Rights Reserved by MedPath